Noticias y vídeos - LSK - Inglés

Veeva Systems (NYSE: VEEV) announced that LSK Global Pharma Services Co. Ltd , a leading Korean contract research organization (CRO), has adopted Veeva Vault eTMF , Veeva Vault CTMS , and Veeva SiteVault Free . With Veeva Vault Clinical applications, LSK Global PS can streamline trial management and remotely collaborate with study monitors for document review and verification. “As a leading CRO, our aim is to run faster, more efficient trials,” said Young-Jack Lee, Ph.D. and president of LSK...

Crypto.com Lists Lisk (LSK) - Best place to purchase LSK at true cost with zero fees and markups PR Newswire HONG KONG, Sept. 11, 2019 HONG KONG , Sept. 11, 2019 /PRNewswire/ -- Crypto.com , the pioneering payments and cryptocurrency platform, announced today that it has listed Lisk (LSK) to its App. LSK joins a growing list of cryptocurrencies and stablecoins on the Crypto.com platform, such as Bitcoin (BTC), Ether (ETH), Litecoin (LTC), XRP, TrueUSD (TUSD), PAXOS (PAX), and its own MCO and CRO...

Crypto.com Lists Lisk (LSK) PR Newswire HONG KONG, Sept. 11, 2019 - Best place to purchase LSK at true cost with zero fees and markups HONG KONG , Sept. 11, 2019 /PRNewswire/ -- Crypto.com , the pioneering payments and cryptocurrency platform, announced today that it has listed Lisk (LSK) to its App. LSK joins a growing list of cryptocurrencies and stablecoins on the Crypto.com platform, such as Bitcoin (BTC), Ether (ETH), Litecoin (LTC), XRP, TrueUSD (TUSD), PAXOS (PAX), and its own MCO and CRO...

LSK BioPharma and Jiangsu Hengrui Medicine Announce FDA Clearance to Initiate a Phase 3 Clinical Trial in Advanced Hepatocellular Carcinoma (HCC) PR Newswire SALT LAKE CITY and SHANGHAI, April 8, 2019 SALT LAKE CITY and SHANGHAI , April 8, 2019 /PRNewswire/ -- LSK BioPharma (or "LSKB"), a US-based biopharmaceutical firm and Jiangsu Hengrui Medicine, Co., Ltd. (SHA:600276, or "Hengrui"), one of the largest and most innovative fully-integrated biopharmaceutical companies based in China , today...

LSK BioPharma and Jiangsu Hengrui Medicine Announce Global Clinical Collaboration to Evaluate the Combination of Anti-Angiogenesis and Immuno-Oncology Therapy for Patients with Advanced Hepatocellular Carcinoma (HCC) PR Newswire SALT LAKE CITY and SHANGHAI, Oct. 21, 2018 SALT LAKE CITY and SHANGHAI , Oct. 21, 2018 /PRNewswire/ -- LSK BioPharma (or "LSKB"), a US-based biopharmaceutical firm and Jiangsu Hengrui Medicine, Co., Ltd. (SHA:600276, or "Hengrui"), one of the largest and most innovative...